Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


The TAK-448-2001 study evaluated whether treatment with the long-acting kisspeptin analogue TAK-448 could correct low testosterone levels in men with type 2 diabetes.


Open-label, adaptive design assessing serum testosterone responses to varying frequencies and doses of TAK-448 in overweight men with hypogonadotropic hypogonadism.


TAK-448 acutely stimulated serum testosterone secretion in a dose dependent manner, but no regimen could be identified that maintained testosterone secretion within the normal range. The abstract is available here.